Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.
about
Current perspectives on HIV-1 antiretroviral drug resistanceHIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionProbing the molecular mechanism of action of the HIV-1 reverse transcriptase inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) using pre-steady-state kineticsMutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication.Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosineIntracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations.mip1 containing mutations associated with mitochondrial disease causes mutagenesis and depletion of mtDNA in Saccharomyces cerevisiaeHIV-1 reverse transcriptase and antiviral drug resistance. Part 2.Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.Biochemical mechanism of HIV-1 resistance to rilpivirine.Mutations in human DNA polymerase γ confer unique mechanisms of catalytic deficiency that mirror the disease severity in mitochondrial disorder patients.Mutations M184V and Y115F in HIV-1 reverse transcriptase discriminate against "nucleotide-competing reverse transcriptase inhibitors".Thymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.Targets for inhibition of HIV replication: entry, enzyme action, release and maturation.Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion.Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.Computational model of hepatitis B virus DNA polymerase: molecular dynamics and docking to understand resistant mutations.Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapyThe impact of molecular manipulation in residue 114 of human immunodeficiency virus type-1 reverse transcriptase on dNTP substrate binding and viral replication.Insights into DNA substrate selection by APOBEC3G from structural, biochemical, and functional studies.
P2860
Q26852626-3D6D3205-E3AD-49C5-9123-863C1AA8699CQ28478993-6EF2F0FF-1B18-40DD-A5A4-52C91FBE0C5DQ33610945-EC8AA4CB-3E42-4C46-B293-BFA113208652Q33743954-30D5F740-4620-4B83-940B-8ED2CD799279Q33769970-58A46D7F-F709-4B12-A873-2159839F5214Q33770095-645150F2-F379-4801-9B4D-56630AF0B5E8Q33832860-B134DC0B-2C69-4429-9960-8A9F71ACEE74Q33900459-9E8CCE1F-C504-4E77-BFE9-E201775EFBA9Q33987492-9E772B97-4EA0-4E33-9E0B-66D88F055C94Q35566910-8C5AB891-3FC4-42D1-999F-2FFE21BB1E87Q35917530-8F7EFED9-1784-44C6-B840-FDCE67915945Q36057386-55EF118B-4723-46DB-A782-3730C592F9B6Q36368294-158B2A7B-649C-4198-86C2-F670F251E4CFQ36626862-83688DAB-9C6B-4E1B-96AC-3ACE365B526BQ36949351-2590B1F4-D289-4418-A307-38066146DC94Q37432131-5F87CA06-9F87-425F-B667-72F71FE5EDEAQ37979697-6AA851A2-E052-49F1-9277-C0D0708D959FQ38344427-F46C9C7A-FD27-4ADD-AE71-6E658398A0D5Q39345907-0147F374-81B8-4AA4-822C-69D0BDE70D00Q39664167-53508629-3AEB-4EB3-8FDE-F52086C57E87Q39796529-CB353B5C-2636-45B2-A0DA-5394BA1D1E47Q40291210-42D244F9-4919-473B-BE01-366904DB055BQ40454877-0F9F0F41-5773-404D-A817-BCFFB2C743BAQ40721745-BA4E4969-D166-46CD-A384-198AE938032EQ41474077-D4B8B034-5304-4230-850E-B640EF43F8D9Q41862836-7E1BDEA4-6D12-46D6-8B66-548DAF2E757BQ42430831-D2C35BAE-5AC1-4B60-A337-BCA7E963703FQ42939817-D5C7EDA2-1539-4F06-8C3E-AA5E655CA020Q52621974-319C144A-A6C0-4824-A583-EB110EF131E3
P2860
Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Mechanistic studies to underst ...... rse transcriptase to abacavir.
@en
Mechanistic studies to underst ...... rse transcriptase to abacavir.
@nl
type
label
Mechanistic studies to underst ...... rse transcriptase to abacavir.
@en
Mechanistic studies to underst ...... rse transcriptase to abacavir.
@nl
prefLabel
Mechanistic studies to underst ...... rse transcriptase to abacavir.
@en
Mechanistic studies to underst ...... rse transcriptase to abacavir.
@nl
P2860
P356
P1476
Mechanistic studies to underst ...... rse transcriptase to abacavir.
@en
P2093
Aravind Basavapathruni
Karen S Anderson
P2860
P304
40479-40490
P356
10.1074/JBC.M205303200
P407
P577
2002-08-09T00:00:00Z